Trials / Active Not Recruiting
Active Not RecruitingNCT05509790
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
A Phase 1 Study of LY3484356 in Chinese Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of LY3484356 in Chinese participants with advanced breast cancer. Participants must have breast cancer that is estrogen receptor positive (ER+), HER2 negative (HER2-). The purpose of this study is to measure how much LY3484356 gets into the bloodstream and how long it takes the body to remove it. The safety and effectiveness of LY3484356 will also be studied. Participation could last up to 28 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3484356 | Administered orally. |
Timeline
- Start date
- 2022-10-09
- Primary completion
- 2024-02-18
- Completion
- 2026-12-01
- First posted
- 2022-08-22
- Last updated
- 2026-04-13
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05509790. Inclusion in this directory is not an endorsement.